This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges
BMC Medicine Open Access 15 May 2023
-
In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia
Scientific Reports Open Access 21 October 2022
-
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia
Nature Communications Open Access 28 January 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O’Brien S et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo clinic experience. Blood 2009; 114: 957–964.
Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473–4479.
Zainuddin N, Murray F, Kanduri M, Gunnarsson R, Smedby KE, Enblad G et al. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 2011; 35: 272–274.
Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010; 24: 211–215.
Rodriguez A, Villuendas R, Yanez L, Gomez ME, Diaz R, Pollan M et al. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia 2007; 21: 1984–1991.
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793–1801.
Kienle D, Benner A, Laufle C, Winkler D, Schneider C, Buhler A et al. Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica 2010; 95: 102–109.
Stamatopoulos B, Haibe-Kains B, Equeter C, Meuleman N, Soree A, De Bruyn C et al. Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Haematologica 2009; 94: 790–799.
Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010; 16: 903–908.
Flach H, Rosenbaum M, Duchniewicz M, Kim S, Zhang SL, Cahalan MD et al. Mzb1 protein regulates calcium homeostasis, antibody secretion, and integrin activation in innate-like B cells. Immunity 2010; 33: 723–735.
Acknowledgements
We would like to thank the MCR, MCC and IBE for cooperation. Further we would like to thank the Laboratory for Leukemia Diagnostics for providing the microarray data and patient samples and, especially, Claudia and Torsten Haferlach, Frank Dicker, Alexander Kohlmann and Susanne Schnittger. Furthermore, we would like to thank Natalia Kerber and Evelyn Zellmeier for assistance in sample processing. T Herold was supported by the KL Weigand'schen Stiftung, the Curt-Bohnewands- Fonds and the Georg und Traud Gravenhorst–Stiftung and by the Deutsche Forschungsgemeinschaft, collaborative research center SFB 684 ‘Molecular mechanisms of normal and malignant hematopoiesis’. This work was in part supported by grants from the German Ministry of Research and Education (BMBF; 01GS0876) and the Deutsche Forschungsgemeinschaft (SFB 684) to C. Buske and SK Bohlander. V Jurinovic was supported by the German José Carreras Leukaemia Foundation (DJCLS H06/04V) and the BMBF medical systems biology project HaematoSYS (BMBF-FKZ 03415452I).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Herold, T., Jurinovic, V., Metzeler, K. et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 25, 1639–1645 (2011). https://doi.org/10.1038/leu.2011.125
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.125
This article is cited by
-
Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges
BMC Medicine (2023)
-
In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia
Scientific Reports (2022)
-
Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target
Leukemia (2021)
-
Blood cancer driver Musashi-2 as therapeutic target in chronic lymphocytic leukemia
Leukemia (2021)
-
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia
Nature Cancer (2021)